PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
38.98%
Positive EBIT growth while CRVO is negative. John Neff might see a substantial edge in operational management.
38.60%
Positive operating income growth while CRVO is negative. John Neff might view this as a competitive edge in operations.
30.20%
Net income growth comparable to CRVO's 32.36%. Walter Schloss might see both following similar market or cost trajectories.
30.24%
EPS growth of 30.24% while CRVO is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
30.24%
Diluted EPS growth of 30.24% while CRVO is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-238.96%
Negative OCF growth while CRVO is at 35.89%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-238.96%
Negative FCF growth while CRVO is at 35.89%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-778.56%
Negative 10Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-778.56%
Negative 5Y OCF/share CAGR while CRVO is at 0.00%. Joel Greenblatt would question the firm’s operational model or cost structure.
-778.56%
Negative 3Y OCF/share CAGR while CRVO stands at 0.00%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-3564.11%
Negative 10Y net income/share CAGR while CRVO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-3564.11%
Negative 5Y net income/share CAGR while CRVO is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-3564.11%
Negative 3Y CAGR while CRVO is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-1192.22%
Negative equity/share CAGR over 10 years while CRVO stands at 0.00%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.
-1192.22%
Negative 5Y equity/share growth while CRVO is at 0.00%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-1192.22%
Negative 3Y equity/share growth while CRVO is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.08%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-7.18%
We have a declining book value while CRVO shows 0.00%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
20.52%
We have some new debt while CRVO reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.
No Data
No Data available this quarter, please select a different quarter.
-41.39%
We cut SG&A while CRVO invests at 31.71%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.